News
today announced the approval for its pivotal ENIGMA-TRS Phase III development program evaluating evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback